Updates in Refractory Status Epilepticus. (8th May 2018)

• Record Type: Journal Article
• Authors: Marawar, Rohit; Basha, Maysaa; Mahulikar, Advait; Desai, Aaron; Suchdev, Kushak; Shah, Aashit
• Other Names: Lazaridis Christos Academic Editor.
• Is Part Of: Critical care research and practice. Volume 2018(2018)
• Publication Date: 2018-05-08
• Subjects: Critical care medicine -- Periodicals; 616.028
• DOI: 10.1155/2018/9768949
• Languages: English
• ISSNs: 2090-1305

Abstract

Abstract : Refractory status epilepticus is defined as persistent seizures despite appropriate use of two intravenous medications, one of which is a benzodiazepine. It can be seen in up to 40% of cases of status epilepticus with an acute symptomatic etiology as the most likely cause. New-onset refractory status epilepticus (NORSE) is a recently coined term for refractory status epilepticus where no apparent cause is found after initial testing. A large proportion of NORSE cases are eventually found to have an autoimmune etiology needing immunomodulatory treatment. Management of refractory status epilepticus involves treatment of an underlying etiology in addition to intravenous anesthetics and antiepileptic drugs. Alternative treatment options including diet therapies, electroconvulsive therapy, and surgical resection in case of a focal lesion should be considered. Short-term and long-term outcomes tend to be poor with significant morbidity and mortality with only one-third of patients reaching baseline neurological status.